Business
Business Update
Business Update.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING FOR THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH, CEO.\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nBusiness Update\n \nLONDON and SALT LAKE CITY, August 21, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces it has been notified that KidneyIntelX™ is included in the draft Kidney Disease Improving Global Outcomes (KDIGO) 2023 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (the \"KDIGO 2023 Guideline\"). KDIGO guideline development follows an explicit process to translate global scientific evidence review and appraisal into practical recommendations for clinicians and patients. A 30 day open public comment period on the KDIGO draft 2023 guidelines that began in July is now closed, and the final version of these kidney disease guidelines is expected to be released in the fourth quarter of 2023.\n \nThe KDIGO 2023 Guideline is a comprehensive update of the current KDIGO guideline for kidney disease evaluation and management issued in 2012. The aim of the update is to generate a useful resource that clearly and concisely addresses relevant questions with actionable recommendations based on a formal evidence review and consensus-based practice points to guide clinical practice. Guideline recommendations were based on systematic reviews of relevant clinical trials and publications. Appraisal of the quality of the evidence and the strength of recommendations for graded recommendations followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.\n \nRenalytix believes that inclusion of KidneyIntelX in the KDIGO 2023 Guideline would be significant for broader adoption, clinical acceptance, and reimbursement of KidneyIntelX testing for risk assessment of patients with type 2 diabetes and early-stage kidney disease in the United States and abroad. \n \nKDIGO is a global non-profit organization developing and implementing evidence-based clinical practice guidelines in kidney disease that are followed by clinicians in the United States and around the world. It is an independent, foundation incorporated in Belgium and accountable to t...